Adaptimmune, a leader in T-cell therapy, has clinical trials ongoing for multiple proprietary SPEAR T-cells in solid tumor indications. The Company also has a T-cell program partnered with GSK, which has already shown preliminary evidence of tumor reduction in patients with synovial sarcoma and multiple myeloma.
Our proprietary SPEAR T-cell platform has generated a strong pipeline of affinity-enhanced T-cell therapies, with multiple INDs open. We use these therapies to harness the body’s own immune system to find and destroy diseased cells.
Our SPEAR TCR therapies offer promise to patients that often have no other options. We are working hard to make that promise a reality.